<i>In Vitro</i><scp>PET</scp>/<scp>MRI</scp> Diagnosis and Targeted Chemotherapy for Cancer Using Radiolabeled Nanoprobe : A Theragnostic Approach

Cho, Bo-Bae; Moon, Mi Mi; Raj, C. Justin; Hwang, Sang Hyuck; Lee, Jung Hoon; Jung, Soon Jae; Kim, Byung Chul; Yu, Kook Hyun

doi:10.1002/bkcs.10794

Cited by 4 publications

(1 citation statement)

References 29 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multifunctional folic acid-modified dendrimers labeled with 64 Cu and using a DOTA chelator has also been reported by Ma et al [ 46 ], however, high liver and kidney uptake and only moderate KB tumor uptake was obtained. Folate-conjugated iron oxide nanoparticles radiolabeled with either 64 Cu or 68 Ga for imaging purposes have been prepared and biologically evaluated in cell studies showing high specific interaction between FA on the nanoparticles and the FR of the FR-positive cells [ 51 , 52 ]. The in vivo performance of these radiolabeled folate-conjugated nanoparticles has not been reported and remains to be investigated.…”

Section: Structure-activity-relationship and Library Design Of Radmentioning

confidence: 99%

Development of Folate Receptor−Targeted PET Radiopharmaceuticals for Tumor Imaging—A Bench-to-Bedside Journey

Boss

Ametamey

2020

Cancers

View full text Add to dashboard Cite

The folate receptor-α (FR-α) is overexpressed in many epithelial cancers, including ovary, uterus, kidneys, breast, lung, colon and prostate carcinomas, but shows limited expression in normal tissues such as kidneys, salivary glands, choroid plexus and placenta. FR-α has therefore emerged as a promising target for the delivery of therapeutic and imaging agents to FR-positive tumors. A series of folate-based PET (positron emission tomography) radiopharmaceuticals have been developed for the selective targeting of FR-positive malignancies. This review provides an overview on the research progress made so far regarding the design, radiosynthesis and the utility of the folate-derived PET radioconjugates for targeting FR-positive tumors. For the most part, results from folate radioconjugates labeled with fluorine-18 (t1/2 = 109.8 min) and gallium-68 (t1/2 = 67.7 min) have been presented but folates labeled with “exotic” and new PET radionuclides such as copper-64 (t1/2 = 12.7 h), terbium-152 (t1/2 = 17.5 h), scandium-44 (t1/2 = 3.97 h), cobalt-55 (t1/2 = 17.5 h) and zirconium-89 (t1/2 = 78.4 h) are also discussed. For tumor imaging, none of the reported PET radiolabeled folates reported to date has made the complete bench-to-bedside journey except [18F]AzaFol, which made it to patients with metastatic ovarian and lung cancers in a multicenter first-in-human trial. In the near future, however, we expect more clinical trials with folate-based PET radiopharmaceuticals given the increasing clinical interest in imaging and the treatment of FR-related malignancies.

show abstract

Section: Structure-activity-relationship and Library Design Of Radmentioning

confidence: 99%

Development of Folate Receptor−Targeted PET Radiopharmaceuticals for Tumor Imaging—A Bench-to-Bedside Journey

Boss

Ametamey

2020

Cancers

View full text Add to dashboard Cite

show abstract

Nanoprobes for PET/MR Imaging

Liu,

Wang,

Gao

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

The development of clinical imaging techniques significantly improves diagnostic accuracy and provides guidance for personalized treatment of individuals. However, every single imaging modality has its distinct drawbacks that cannot fully fulfil the diagnosis requirement. Thus, rational combination of different imaging modalities can achieve more comprehensive information of disease and in this way provide better personalized treatment strategy. The hybrid PET/MRI has drawn increasing attention since its first clinical application. Imaging probes play an essential role in achieving qualified figures with accurate information of diseases. The application of nanotechnology promotes the development of versatile molecular probes for PET/MRI technique. Though there is an emerging clinical requirement, only a small number of multimodal PET/MRI probes have been investigated in preclinical research. Thus, in this review, we try to thoroughly summarize the nano‐sized PET/MRI probes on their design, preparation and biological application. By discussing the strength and limitations of these current available PET/MRI multimodal probes, we aimed to figure out the further research direction and promote the possible clinic translation of the novel PET/MRI probes.This article is protected by copyright. All rights reserved

show abstract

HER2 inhibition efficiency of 6-amino-2-methyl-2-phenethyl-2H-benzopyran and feasibility of the ⁶⁴Cu-labeled benzopyran derivative in cancer diagnosis

et al. 2019

View full text Add to dashboard Cite

show abstract

In VitroPET/MRI Diagnosis and Targeted Chemotherapy for Cancer Using Radiolabeled Nanoprobe : A Theragnostic Approach

Cited by 4 publications

References 29 publications

Development of Folate Receptor−Targeted PET Radiopharmaceuticals for Tumor Imaging—A Bench-to-Bedside Journey

Development of Folate Receptor−Targeted PET Radiopharmaceuticals for Tumor Imaging—A Bench-to-Bedside Journey

Nanoprobes for PET/MR Imaging

HER2 inhibition efficiency of 6-amino-2-methyl-2-phenethyl-2H-benzopyran and feasibility of the ⁶⁴Cu-labeled benzopyran derivative in cancer diagnosis

Contact Info

Product

Resources

About

In VitroPET/MRI Diagnosis and Targeted Chemotherapy for Cancer Using Radiolabeled Nanoprobe : A Theragnostic Approach

Cited by 4 publications

References 29 publications

Development of Folate Receptor−Targeted PET Radiopharmaceuticals for Tumor Imaging—A Bench-to-Bedside Journey

Development of Folate Receptor−Targeted PET Radiopharmaceuticals for Tumor Imaging—A Bench-to-Bedside Journey

Nanoprobes for PET/MR Imaging

HER2 inhibition efficiency of 6-amino-2-methyl-2-phenethyl-2H-benzopyran and feasibility of the 64Cu-labeled benzopyran derivative in cancer diagnosis

Contact Info

Product

Resources

About

HER2 inhibition efficiency of 6-amino-2-methyl-2-phenethyl-2H-benzopyran and feasibility of the ⁶⁴Cu-labeled benzopyran derivative in cancer diagnosis